Sotrovimab

Summary

Sotrovimab (CHEMBL4650524) is an approved antibody (ATC J06BD05); indicated across 2 conditions including severe acute respiratory syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: J06BD05
• Indications: 2 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650524
Name	Sotrovimab
Type	Antibody
Max phase	4
ATC	J06BD05

Also known as: GSK-4182136, GSK4182136, Sotrovimab, Vir-7831, VIR-7831, VIR7831, Xevudy, SOTROVIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV Spike glycoprotein	Binding

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	4	MONDO:0005091	MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2	5
Not specified	4
PHASE1	3
PHASE4	2
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04790786	PHASE4	TERMINATED	UPMC OPTIMISE-C19 Trial, a COVID-19 Study
NCT05305651	PHASE4	COMPLETED	Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
NCT04381936	PHASE3	RECRUITING	Randomised Evaluation of COVID-19 Therapy
NCT04501978	PHASE3	COMPLETED	ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04545060	PHASE2/PHASE3	COMPLETED	VIR-7831 for the Early Treatment of COVID-19 in Outpatients
NCT04870333	PHASE2/PHASE3	COMPLETED	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
NCT04913675	PHASE3	TERMINATED	Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
NCT05205759	PHASE3	TERMINATED	Non-inferiority Trial on Monoclonal Antibodies in COVID-19
NCT05321394	PHASE3	COMPLETED	Non-inferiority Trial on Treatments in Early COVID-19
NCT05780281	PHASE3	COMPLETED	VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT04746183	PHASE1/PHASE2	RECRUITING	AGILE (Early Phase Platform Trial for COVID-19)
NCT05041907	PHASE2	RECRUITING	Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT04634409	PHASE2	COMPLETED	A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT04779879	PHASE2	COMPLETED	Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
NCT05124210	PHASE2	TERMINATED	Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
NCT05210101	PHASE2	COMPLETED	A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
NCT04988152	PHASE1	COMPLETED	A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
NCT05135650	PHASE1	TERMINATED	Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
NCT05280717	PHASE1	TERMINATED	Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
NCT05195060	Not specified	COMPLETED	TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
NCT05235347	Not specified	NO_LONGER_AVAILABLE	Sotrovimab Expanded Access Treatment Protocol (COVID-19)
NCT05268601	Not specified	COMPLETED	COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
NCT05398718	Not specified	UNKNOWN	Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).